AUS
NZ
UK
CA
USA
IND
Highlights
Indivior PLC confirms it will delist from the London Stock Exchange
The company cites reduced complexity and stronger US trading volumes
Nasdaq now serves as Indivior’s sole primary listing
Pharmaceutical group Indivior PLC (LON:INDV), part of the FTSE 350 index, is preparing to withdraw its listing from the London Stock Exchange (LSE), following its transition to a primary listing on the Nasdaq index (NASDAQ:INDV).
Indivior, which develops prescription treatments targeting opioid dependence, stated that its strategic direction now aligns more closely with the US market. The company attributed its decision to the dominance of its US-based revenue streams and operations. A significant portion of the firm’s business is now concentrated in North America, prompting a review of its dual listing structure.
By moving away from a secondary listing on the LSE, Indivior aims to streamline its corporate structure. The company highlighted that maintaining two listings had introduced additional administrative burdens and complexities. The upcoming delisting from London will leave the Nasdaq as its sole listing venue.
Liquidity Shift to US Trading Platforms
According to Indivior, liquidity levels on the Nasdaq far exceed those on the LSE. The shift in trading volumes has led the company to determine that its shares are more actively bought and sold in the US. This trend has influenced the group’s view on the need to maintain access to UK capital markets.
The company’s chair stated that a single Nasdaq listing would be more representative of the business’s geographical footprint. Shareholders were informed that the move is expected to streamline governance and reduce associated costs.
Context of Broader Market Activity
The announcement positions Indivior among a number of companies that have reevaluated their listing venues in recent periods. Some firms have opted to concentrate listings in the US to match the location of their primary customer base and operational infrastructure.
Despite Indivior’s exit, the London Stock Exchange continues to attract new entities. Anglo American’s platinum business spin-off, Valterra, has entered the market as a standalone entity. This move indicates that while some firms are consolidating operations abroad, others continue to see value in maintaining or initiating a UK presence.
Implications for FTSE 350 Composition
Indivior’s departure from the LSE is expected to lead to changes in the FTSE 350 index composition. Companies listed on the index must maintain a listing on the LSE, and removals are typically followed by rebalancing exercises. This process may open up index space for other qualifying firms with a primary UK listing.
With Indivior’s operational focus remaining in the pharmaceutical sector and its strategic direction centred around the US, its market status has evolved. The transition to a sole Nasdaq listing reflects this shift and repositions the company in terms of regulatory and shareholder engagement requirements.
